Experience

SETOP S.A.

• Chile
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Principal Scientist

  • Nov 2021 - Present



TYG ONCOLOGY LTD.

• United Kingdom
• Biotechnology Research

• Advisory Board

  • Sep 2020 - Present



OncoQR ML

• Walterstrasse 21, 3011 Irenental, Austria

• Managing Director

  • Apr 2014 - Aug 2021

  · Responsible of Research and development of the vaccine platform against oncologic targets and allergy · Active participation in the development of a vaccine against pancreatic cancer until human trials. · Process map and analytics development. · Liaison to CMOs and CROs for technology transfer and product development until Clinical Trials · Preparation and evaluation of preclinical trials in non-human primates, mouse and other animal models with the subsequent evaluation of safety data, humoral- and cellular response. · Project managing of new vaccine candidates · Supervision of assay development: cell-based assays (CTL, ADCC, CDC, etc.). FACS data analysis of PBMCs, Immunocytochemistry, RT-PCR, cytokine release by pDCs, etc.. · Actively involved in grant applications Publication: TLR9-mediated activation of dendritic cells by CD32 targeting for the generation of highly immunostimulatory vaccines. Sepulveda-Toepfer JA, Pichler J, Fink K, Sevo M, Wildburger S, Mudde-Boer LC, Taus C, Mudde GC. Hum Vaccin Immunother. 2019; 15(1):179-188. Show less



Valneva

• France
• Biotechnology Research
• 400 - 500 Employee

• Snr. Staff Scientist

  • Nov 2012 - May 2014

  R&D at the human monoclonal antibody group: endogenous human monoclonal antibodies platform transfer and optimisation. antibody project scouting vaccine project scouting project transfer Publication: Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. Beerli RR, Bauer M, Fritzer A, Rosen LB, Buser RB, Hanner M, Maudrich M, Nebenfuehr M, Sepulveda Toepfer JA, Mangold S, Bauer A, Holland SM, Browne SK, Meinke A. MAbs. 2014;6(6):1608-20. Show less



S-TARget therapeutics

• Austria
• Biotechnology Research

• Group Leader

  • Jan 2012 - Nov 2012

  R&D of S-TARget’s proprietary S-TIR technology platform and SG100, S-TARget's first preventive and therapeutic vaccine. SG100, like all vaccines from S-TIR, is human specific and targets allergies caused by house dust mites. The vaccine has been proven to be safe and effective in non human primates suffering from severe house dust mite induced allergic asthma. R&D of S-TARget’s proprietary S-TIR technology platform and SG100, S-TARget's first preventive and therapeutic vaccine. SG100, like all vaccines from S-TIR, is human specific and targets allergies caused by house dust mites. The vaccine has been proven to be safe and effective in non human primates suffering from severe house dust mite induced allergic asthma.



F-star, an invoX company

• United Kingdom
• Biotechnology
• 1 - 100 Employee

• Principal Scientist

  • Feb 2011 - Jan 2012

  -Supervision of performance of projects: internal and external.-development of assays for evaluating relevant binders.-design of strategies of leads, identification and affinity maturation.-transfer of technology.

• Senior Scientist II

  • Jan 2009 - Feb 2011

  -Design and construction of naive libraries (yeast display).-Optimization of yeast surface display technology.-Identification and affinity maturation of binders against diverse targets of pharmaceutical interest.-Characterization of binders.-Therapeutic focus: oncologic and autoimmune diseases.-Set-up a reliable platform for candidates identification and development -Responsible for 3 technical assistants.

• Senior Scientist

  • Apr 2008 - Jan 2009

  - Built a yeast-based platform to identify NBEs- Design and construction of synthetic libraries (yeast display)- Optimization of yeast display technology- Identification of binders against diverse targets of pharmaceutical interest



Tufts University

• United States
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • Jun 2005 - Mar 2008

  Construction of diverse antibody (scFv) libraries using phage display platform from different immunized animal models (sheep, mice, rat, alpaca). affinity maturation of peptides (phage display) Targets: Botulinum toxin, Schistosoma mansoni Screening and characterization of binders. Publications; Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Tremblay JM, Kuo CL, Abeijon C, Sepulveda J, Oyler G, Hu X, Jin MM, Shoemaker CB. Toxicon, 2010 Nov; 56(6):990-8. Schistosoma mansoni host-exposed surface antigens characterized by sera and recombinant antibodies from schistosomiasis resistant rats. Jorge Sepulveda, Jacqueline M. Tremblay, Patrick J. Skelly, Charles B. Shoemaker. International Journal of Parasitology, 2010 Oct; 40(12):1407-17. Efficient serum clearance of botulinum neurotoxin using a pool of small antitoxin binding agents. Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB. Infect. Immun. 2010 Feb; 78(2):756-63. Design and testing of PCR primers for the construction of scFv libraries representing the immunoglobulin repertoire of rats. Jorge Sepulveda and Charles B. Shoemaker. Journal of Immunological Methods, 2008, 332(1-2):92-102. Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). David R. Maass, Jorge Sepulveda, Anton Pernthaner, Charles B. Shoemaker. Journal of Immunological Methods, 2007, 324(1-2):13-25. Tufts University, Ref: Dr. Charles Shoemaker Show less



ICGEB

• Italy
• Biotechnology Research
• 300 - 400 Employee

• Postdoctoral Fellow

  • 2001 - Jun 2005

  Antibody engineering and development of a novel binding molecule:VHD library construction (phage display technology) Screening and characterization of binders. Department of Molecular Immunology, International Centre of Genetic Engineering and Biotechnology, Trieste, Italy Publications: Selection of an Antibody Library Identifies a Pathway to Induce Immunity by Targeting CD36 on Steady-State CD8{alpha}+ Dendritic Cells. Tagliani E, Guermonprez P, Sepúlveda J, López-Bravo M, Ardavín C, Amigorena S, Benvenuti F, Burrone OR. J Immunol. , 2008, 180(5):3201-9. Specific recognition of a dsDNA sequence motif by an immunoglobulin VH homodimer. Jin H, Sepúlveda J and Burrone OR. Protein Sci., 2004 Dec 1; 13: 3222-322. Selection and characterisation of binders based on homodimerisation of immunoglobulin VH domains. Jin H, Sepúlveda J and Burrone OR. FEBS letter, 2003 Nov 20; 554(3): 323-329. Binders Based on Dimerised Immunoglobulin VH Domains. Sepúlveda J, Jin H, Sblattero D, Bradbury A and Burrone OR. J Mol Biol 2003 Oct 17; 333(2): 355–365. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepúlveda J, Burrone O, Neri D, Zardi L. Int J Cancer. 2002 Nov 1; 102(1):75-85. Membrane immunoglobulins are stabilized by interchain disulfide bonds occurring within the extracellular membrane-proximal domain. Bestagno M, Vangelista L, Mandiola PA, Mukherjee S, Sepúlveda J, Burrone OR. Biochemistry. 2001 Sep 4; 40(35):10686-10692. Ref: Dr. Oscar Burrone Show less



Universidad de Concepción

• Chile
• Higher Education
• 700 & Above Employee

• Assistant Professor

  • 1992 - 2001

  Department of Clinical Biochemistry and Immunology, Faculty of Pharmacy, University of Concepción, Concepción, Chile Publications: An immunoenzymatic procedure for human apo B-containing particles quantification using monoclonal antibodies. Bustos P, Calvo C, Ulloa N, Quiroga A, Sepúlveda J. Hybridoma. 1998 Aug; 17(4):395-401. Increased activity of lecithin:cholesterol acyltransferase during short-term oral estrogen progestin replacement therapy in a group of postmenopausal women. Ulloa N, Verdugo C, Rios M, Sepúlveda J, Sepúlveda S, Naveas R, Calvo C. Metabolism. 1998 Mar; 47(3):297-300. A monoclonal antibody-based enzyme immunoassay for the measurement of native and glycated apolipoprotein B-containing particles. Calvo C, Bustos P, Giraudo P, Ulloa N, Sepúlveda J, Verdugo C, Toledo L. Journal of Atherosclerosis and Thrombosis. 1997; 4(1):45-9. Development of monoclonal antibodies for the selective isolation of human plasma apolipoprotein A-containing particles. Calvo C, Bustos P, Sepúlveda J, Ulloa N, Sepúlveda V. Hybridoma. 1995 Dec; 14(6):603-8. Show less